Jersey Shore Ready ...
Health Care: Drugs
Regeneron Pharmaceuticals Inc. (REGN: NASDAQ)
$250.31 -4.56 | -1.79%
05/24/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 230.28M | 483.61M | 112.57M | 207.08M |
| Receivables | 693.12M | 103.04M | 93.11M | 65.57M |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 1.21B | 652.88M | 357.62M | 425.51M |
| Property, Plant & Equipment, Gross | 560.45M | 526.09M | 478.76M | 372.45M |
| Accumulated Depreciation & Depletion | 180.51M | 158.14M | 131.31M | 112.78M |
| Property, Plant & Equipment, Net | 379.94M | 367.96M | 347.45M | 259.68M |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 302.52M | 302.75M | 384.36M | 56.02M |
| Total Non-Current Assets | 874.48M | 670.71M | 731.81M | 315.69M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 2.08B | 1.32B | 1.09B | 741.20M |
| Accounts Payable | 38.93M | 27.74M | 2.25M | 19.82M |
| Short Term Debt | 1.37M | 1.01M | 675.00K | 0.00 |
| Other Current Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Liabilities | 163.55M | 148.27M | 109.06M | 93.58M |
| Long Term Debt | 296.52M | 275.02M | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 215.60M | 255.05M | 293.21M | 250.86M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 671.56M | 689.58M | 452.56M | 250.86M |
| Total Liabilities | 835.10M | 837.85M | 561.62M | 344.44M |
| Preferred Stock Equity | 2.00K | 2.00K | 0.00 | 0.00 |
| Common Stock Equity | 1.25B | 485.73M | 527.82M | 396.76M |
| Common Par | 95.00K | 91.00K | 89.00K | 81.00K |
| Additional Paid In Capital | 1.76B | 1.75B | 1.58B | 1.34B |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -517.05M | -1.27B | -1.05B | -941.10M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | -1.17M | -1.86M | -2.49M | 1.04M |
| Total Capitalization | 1.54B | 760.75M | 527.82M | 396.76M |
| Total Equity | 1.25B | 485.73M | 527.82M | 396.76M |
| Total Liabilities & Stock Equity | 2.08B | 1.32B | 1.09B | 741.20M |
| Total Common Shares Outstanding | 97.29M | 92.80M | 89.42M | 81.11M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 94.68M | 90.61M | 82.93M | 79.78M |
| Diluted Weighted Shares Outstanding | 115.38M | 90.61M | 82.93M | 79.78M |
| Number of Employees | 1950 | 1704 | 1395 | 1029 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with REGN
- Portfolio NameUser Type
- ContributorTechnical Setups for the We...
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- Contributor10 Companies That Prove Sto...
- ContributorDrugs Facing FDA Approval i...
- ContributorEarnings Short Squeeze Play...
- Contributor10 Stocks of Top-Performing...
- ContributorEarnings Short Squeeze Play...
- ContributorRelative Strength Trades fo...
- Contributor10 Stocks That Boosted Firs...
Latest REGN Headlines from TheStreet
- Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard 05.23.13 | 05:05 pm
- 5 Stocks Underperforming Today In The Drugs Industry 05.20.13 | 01:05 pm
- Regeneron Pharmaceuticals Inc. Stock Buy Recommendation Reiterated (REGN) 05.20.13 | 10:05 am
- Regeneron Pharmaceuticals Inc. (REGN): Today's Featured Drugs Laggard 05.15.13 | 05:05 pm
- 3 Stocks Underperforming Today In The Drugs Industry 05.15.13 | 01:05 pm
- Cramer's 'Mad Money' Recap: Stick With What Works 05.14.13 | 08:05 pm
- Cramer's 6 Stocks in 60 Seconds: MNST CLX REGN KR MDRX PG (Update 1) 05.14.13 | 05:05 pm
- Cramer: Biotech Makes a Comeback 05.10.13 | 04:05 pm
- Regeneron Stock Hits New 52-Week High (REGN) 05.10.13 | 11:05 am
- Biotech Is Where the Bucks Are 05.09.13 | 06:05 am
Press Releases for REGN
- BioMed Realty To Develop 297,000 Square Feet In New York Fully Leased To Regeneron Pharmaceuticals - PR Newswire 04.04.13 | 09:04 am
- Regeneron Named World's #1 Biopharmaceutical Employer In Science Magazine Annual Survey - PR Newswire 09.21.12 | 12:09 pm
- Sanofi And Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody - PR Newswire 07.20.12 | 01:07 am
- Sanofi And Regeneron Announce Publication Of Positive Phase 2 Results For Lipid-Lowering PCSK9 Antibody In The Lancet - PR Newswire 05.26.12 | 11:05 am
- Sanofi And Regeneron Announce Regulatory And Clinical Update For ZALTRAP® (aflibercept) - PR Newswire 04.05.12 | 01:04 am
- Sanofi And Regeneron Report Phase 2 Data For Potential First-in-Class Lipid-Lowering PCSK9 Antibody - PR Newswire 03.26.12 | 11:03 am
- Regeneron And Bayer Announce Approval Of EYLEA® (aflibercept) Injection For The Treatment Of Wet Age-Related Macular Degeneration In Australia - PR Newswire 03.08.12 | 04:03 am
- Two Year Results Of Phase 3 Studies With EYLEA⢠(aflibercept) Injection In Wet AMD Show Sustained Improvement In Visual Acuity - PR Newswire 12.05.11 | 02:12 am
- Regeneron And Bayer Initiate Phase 3 Clinical Program For The Treatment Of Wet Age-Related Macular Degeneration In China - PR Newswire 11.28.11 | 02:11 am
- Phase 3 Trial Of ZALTRAP⢠(aflibercept) In Advanced Prostate Cancer To Continue As Planned At Recommendation Of Independent Data Monitoring Committee - PR Newswire 07.07.11 | 07:07 am
Partner Headlines for REGN
- Alkermes Leaps On Study Results, May Offer New Entry - Investor's Business Daily 04.17.13 | 05:04 pm
- Market Close Report: NASDAQ Composite index closes at 3,264.63 up 48.14 points - NASDAQ 04.16.13 | 08:04 pm
- Indexes Finish With Solid Gains; After Hours Heats Up - Investor's Business Daily 04.16.13 | 05:04 pm
- Stocks Hold Near Highs; Regeneron Shoots To New Peak - Investor's Business Daily 04.16.13 | 03:04 pm
- Pockets of Strength In Top Groups, Few Leaders Basing - Investor's Business Daily 04.15.13 | 06:04 pm
- Stocks End With Mild Losses; Nasdaq Rises 2.8% For Week - Investor's Business Daily 04.12.13 | 05:04 pm
- Regeneron's Flagship Drug Treats Blindness In Seniors - Investor's Business Daily 04.11.13 | 05:04 pm
- Buyers Put Money To Work; Dow, S&P 500 Touch Highs - Investor's Business Daily 04.09.13 | 04:04 pm
- Stocks Flat As Early Gains Fade; Regeneron Hits New High - Investor's Business Daily 04.09.13 | 10:04 am
- IBD Big Cap 20 Analysis: Some Stocks Show Resilience - Investor's Business Daily 04.08.13 | 06:04 pm
